Litigation Details for Novo Nordisk Inc. v. Mylan Pharmaceuticals Inc. (D. Del. 2023)
✉ Email this page to a colleague
Novo Nordisk Inc. v. Mylan Pharmaceuticals Inc. (D. Del. 2023)
| Docket | ⤷ Subscribe | Date Filed | 2023-01-27 |
| Court | District Court, D. Delaware | Date Terminated | |
| Cause | 35:271 Patent Infringement | Assigned To | Colm Felix Connolly |
| Jury Demand | None | Referred To | |
| Patents | 8,129,343; 8,536,122 | ||
| Link to Docket | External link to docket | ||
Small Molecule Drugs cited in Novo Nordisk Inc. v. Mylan Pharmaceuticals Inc.
The small molecule drugs covered by the patents cited in this case are ⤷ Subscribe , ⤷ Subscribe , and ⤷ Subscribe .
Details for Novo Nordisk Inc. v. Mylan Pharmaceuticals Inc. (D. Del. 2023)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 0000-00-00 | External link to document | |||
| 2023-01-27 | 1 | Complaint | United States Patent Nos. 8,129,343 (the “’343 Patent”), 8,536,122 (the “’122 Patent”), 9,764,003 (the… THE PATENTS-IN-SUIT U.S. Patent No. 8,129,343 73. The allegations…(the “’003 Patent”), 10,888,605 (the “’605 Patent”), and 11,318,191 (the “’191 Patent”) (collectively…number of patent litigation lawsuits involving the validity and/or infringement of patents held by branded… claim of the Asserted Patents, and/or that the claims of the Asserted Patents allegedly are invalid | External link to document |
| 2023-06-22 | 28 | Notice of Service | Initial Invalidity Contentions Regarding U.S. Patent Nos. 8,129,343; 8,536,122; 9,764,003; 10,888,605; and 11,318,191… 27 January 2023 1:23-cv-00101 Patent - Abbreviated New Drug Application(ANDA) None | External link to document |
| 2023-01-27 | 3 | ANDA Form | Deadline: ________________________ * U.S. Patent No. 8,129,343 expires on 12/5/2031; ;%:% 8<L@GL 7H%… Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) …Received Notice: 12/17/2022. Date of Expiration of Patent: See Attached.Thirty Month Stay Deadline: 6/17/… SUPPLEMENTAL INFORMATION FOR PATENT CASES INVOLVING AN ABBREVIATED NEW DRUG…See Below* Date of Expiration of Patent: ________________________ | External link to document |
| 2023-07-31 | 37 | Claim Construction Chart | regarding U.S. Patent Nos. 8,129,343 (“the ’343 Patent”); 8,536,122 (“the ’122 Patent”); 9,764,003 (“…Copies of the ’343 Patent, ’122 Patent, ’003 Patent, ’605 Patent, and ’191 Patent are attached hereto… A - '343 Patent, # 2 Ex. B - '122 Patent, # 3 Ex. C - '003 Patent, # 4 Ex. D - '605 Patent, # 5 Ex. E…(“the ’003 Patent”); 10,888,605 (“the ’605 Patent”); and 11,318,191 (“the ’191 Patent”) (collectively…Asserted Patents, the specifications of the Asserted Patents, the claims of the Asserted Patents, the file | External link to document |
| 2023-01-27 | 4 | Patent/Trademark Report to Commissioner of Patents | the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 8,129,343 B2 ;8,536,122 B2 ;9,764,003… 27 January 2023 1:23-cv-00101 Patent - Abbreviated New Drug Application(ANDA) None | External link to document |
| 2023-08-08 | 44 | Notice of Service | Initial Invalidity Contentions Regarding U.S. Patent Nos. 8,129,343; 8,536,122; 9,764,003; 10,888,605; and 11,318,191… 27 January 2023 1:23-cv-00101 Patent - Abbreviated New Drug Application(ANDA) None | External link to document |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
